Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.

Your browser appears to have cookies disabled. For the best experience of this website, please enable cookies in your browser

We'll assume we have your consent to use cookies, for example so you won't need to log in each time you visit our site.
Learn more


  • Comment

VOL: 102, ISSUE: 16, PAGE NO: 32

Generic and proprietary names

Generic and proprietary names
- Mefloquine.

- Lariam.

- Active against the erythrocytic stage of the plasmodium species.

- Antimalarial.

- Prophylaxis of malaria in areas with a high risk of chloroquine-resistant falciparum malaria.


- History of neuropsychiatric disorders including depression and convulsions.

- Hypersensitivity to quinine.

- Pregnancy - avoid pregnancy while taking and for three months after.

- Breastfeeding.

- Severe hepatic impairment.

- Cardiac conduction disorders.

- Epilepsy.

- Infants under three months of age or less than 5kg in weight.

Common side-effects
- Nausea, vomiting, diarrhoea and abdominal pain.

- Dizziness and loss of balance.

- Headache.

- Sleep disorders.

- Neuropsychiatric reactions.

- Tinnitus and vestibular disorders.

- Visual disturbances.

- Circulatory and cardiac problems.

- Dyspnoea.

- Myalgia and arthralgia.

- Rash.

- Alopecia.

- Asthenia.

- Fever and malaise.

- Fatigue.

- Loss of appetite.

- Leucopenia or leucocytosis.

- Thrombocytopenia.

- Anticonvulsants.

- Other antimalarial drugs.

- Beta-blockers.

- Calcium-channel blockers.

- Digitalis drugs.

- Tablets.

- Taken only once a week.

- Start 2.5 weeks before entering endemic area and continue for four weeks after leaving.

Nursing considerations
- Mefloquine doses in the BNF may differ from those in product literature.

- Travellers should be informed about adverse reactions and, if they occur, that they should seek medical advice on alternative antimalarials before the next dose is due.

- Travel to malarious areas should be avoided during pregnancy; if it is unavoidable, effective prophylaxis must be used but mefloquine should be avoided as a matter of principle. However, studies of mefloquine use in pregnancy (including in the first trimester) indicate that it can be considered for travel to chloroquine-resistant areas.

- Mefloquine is considered to be appropriate for use by people with renal impairment and does not require dosage reduction.

Patient teaching
- Warn travellers they should still avoid mosquito bites.

- Ensure travellers understand the importance of taking prophylaxis regularly.

- Advise travellers to seek urgent medical attention if ill within one year and especially within three months of return.

- Dizziness or a disturbed sense of balance may affect performance of skilled tasks such as driving.

- The patient information leaflet that describes adverse reactions should always be provided with mefloquine.

Nurses should refer to manufacturer's summary of product characteristics and to appropriate local guidelines

  • Comment

Have your say

You must sign in to make a comment

Please remember that the submission of any material is governed by our Terms and Conditions and by submitting material you confirm your agreement to these Terms and Conditions. Links may be included in your comments but HTML is not permitted.